ATP5PB

Across TCGA pan-cancer cohorts, ATP5PB mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ATP5PB data layer compared with 19 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ATP5PB mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP5PB expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where ATP5PB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.074	0.681	.017	9	view →
LUAD	DFS	Tertile	All	0.455	0.782	.004	5	view →
HNSC	DFS	Quartile	IV	0.893	0.610	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ATP5PB–CCRCC (DFS)

Open the CCRCC breakdown →